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The aim of the study was to evaluate routine management of patients with community-acquired pneumonia (CAP)
with regard to severity patterns, diagnostic approaches and results, as well as initial empiric antimicrobial treatment
and its impact on outcome.
Two hundred and thirty-two consecutive patients with CAP admitted to a primary care hospital were studied
prospectively. Patients were classified according to Fine’s severity score. Severe pneumonia was defined as
admission at the ICU. Diagnostic approaches and initial antimicrobial treatment were judged according to the
guidelines of the European Respiratory Society (ERS).
Fifty-five patients (24%) had mild, 156 (67%) moderate, and 21 (9%) severe CAP. At least one microbial
examination was performed in 124 patients (54%). There was no association between microbial investigation and
severity of CAP. Inadequate initial antimicrobial treatment was significantly more frequent in severe (18/21, 86%),
than in mild (5/55, 9%) and moderate CAP (39/156, 25%, P5 0?0001). Conversely, antimicrobial overtreatment
occurred significantly more often in mild (30/55, 55%) and moderate (77/156, 49%) than in severe CAP (0/21, 0%,
P5 0?0001). Inadequate initial antimicrobial treatment was more frequent in non-responders [18/62 (29%) vs. 31/
170, (18%), RR 1?6 95% CI 0?9–2?6, P=0?07] and was associated with a longer duration of hospitalization (17+11
vs. 14+8 days, P=0?03). Mortality was not aected by inadequate initial antimicrobial treatment [5/62 (8%) vs. 10/
170 (6%), RR 1?4 95% CI 0?5–3?9, P=0?55].
Principal conceptual weaknesses which might be subject to intervention were (1) the hospitalization of patients
with mild pneumonia at low risk of mortality; (2) the lack of association between microbial investigation and
severity of CAP; (3) antimicrobial overtreatment of patients with non-severe CAP; and (4) inadequate antimicrobial
treatment with increased number of primary treatment failures and duration of hospitalization.
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Although community-acquired pneumonia (CAP) con-
tinues to represent a frequent condition, there are ongoing
controversies about the optimal strategy of patient care.
These aect all important corresponding issues, including
criteria for hospitalization, diagnostic approaches, and
initial antimicrobial treatment (1–6). In the era of limited
health care resources, economic aspects gain increasing
priority in these debates.Received 23 July 1999 and accepted in revised form 20 December
1999.
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0954-6111/00/060556+08 $35?00/0Current concepts of management of patients with
CAP generally intend to provide a framework of advice
which is evidence-based from the literature (1–4). Some
of these have already been subject to prospective
validation. For example, recommendations for the
initial antimicrobial treatment in the guidelines of the
American Thoracic Society (ATS) for the initial
management of adult CAP were implemented in patient
care and assessed with regard to cost-eectiveness (7). A
perhaps more simple and pragmatic way to optimize patient
care could be the evaluation of routine management of
CAP in distinct hospital settings. Such an evaluation may
oer the opportunity to detect conceptual weaknesses
which might be subject to future intervention. We thought
that the most recently published European Respiratory
Society (ERS) guidelines (5) and the powerful tool of Fine’s
severity score for CAP (8) would guide such a type of
critical evaluation.# 2000 HARCOURT PUBLISHERS LTD
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CAP in order to evaluate the severity patterns of CAP,
diagnostic approaches and results as well as initial empiric
antimicrobial treatment and its impact on outcome. The
setting of a primary care hospital was chosen since in our
region probably most hospitalized patients with CAP are
treated in these hospitals.
Methods
SETTING
The study was conducted at the Dreifaltigkeits-Kranken-
haus in Wesseling, a primary care hospital with approxi-
mately 200 beds. The Department of Internal Medicine
does not include any speciality. The hospital does not have
a microbiological laboratory on site. No attempt was made to
influence patient management in any phase of hospital stay.
PATIENTS
Between 1 July 1996 and 31 March 1998, all patients with a
diagnosis of community-acquired pneumonia were pro-
spectively recorded. The diagnosis of community-acquired
pneumonia was based on a new infiltrate in a chest
radiograph, symptoms suggestive of a lower respiratory
tract infection, and no alternative diagnosis emerging
during follow-up in a non-immunosuppressed host not
hospitalized during the previous month. Exclusion criteria
were (i) the presence of severe immunosuppression with
inherent risk of opportunistic infections (HIV infection,
neutropenia 516109l71, and organ transplantation); (ii)
patients referred from another hospital after initiation of
antimicrobial treatment; (iii) patients with gross aspiration;
and (iv) patients with pulmonary tuberculosis.
DATA COLLECTION
All data were recorded on standard record sheets by two of
the authors (K.S. and T.K.) who were members of the sta
of the Department of Internal Medicine at the Dreifaltig-
keits-Krankenhaus. On admission, the following demo-
graphic parameters were retrieved: age, gender, admission
from home or nursing-home, smoking habits and alcohol
intake, and comorbid illnesses. Physical examination
parameters included respiratory rate, heart rate, systolic
and diastolic blood pressure, mental confusion defined
according to Fine et al. (8): disorientation with respect to
person, place or time that is to not known to be chronic,
stupor, or coma.
Laboratory parameters included leucocyte count, lactate
dehydrogenase (LDH), blood urea nitrogen, (BUN) hema-
tocrit, sodium, glucose. Further data included: blood gases
(pH, PaO2, PaCO2, PaO2 F1O2), extent and type of
pulmonary infiltrates (uni-vs. bilateral and alveolar vs.
bronchopneumonic) as well as the presence of pleural
eusion, and suspicion of gross aspiration. After discharge
or death, the type of antimicrobial treatment, microbiolo-gical results and outcome variables (duration of hospitali-
zation, requirement for ICU admission and for mechanical
ventilation, survival or death within 30 days of hospital
treatment) were retrieved additionally. Data were recorded
on and entered into a computer database.
DEFINITIONS
Patients were classified according to the severity score of
Fine et al (8). Patients with Fine scores I and II (i.e. a risk of
mortality 51%) were classified as having mild CAP, and
those with Fine scores III–V as having moderate CAP,
unless admitted to the ICU. Since no universally accepted
definition of severe CAP is available, and Fine scores IV
and V were not designed to provide such definition, it was
defined as admission to the ICU within 5 days of hospital
admission.
Adequacy of initial empiric antimicrobial treatment was
defined following the ERS guidelines (5). Modifications
were made according to current German susceptibility
patterns (9). Third or fourth generation quinolones were
not used in any case and, therefore, not considered.
Since mild CAP may have been safely managed at home,
antimicrobial treatment in patients presenting with mild
CAP was judged according to recommendations for
outpatient pneumonia. Thus, monotherapy with aminope-
nicillin, first-generation cephalosporin, macrolide, and
tetracycline was considered adequate, whereas any mono-
therapy with inadequate coverage of Streptococcus pneu-
moniae (second generation quinolones such as ofloxacin
and ciprofloxacin) and Haemophilus influenzae (pencillin G)
was considered inadequate.
In moderate CAP, monotherapy with aminopenicillin or
second- or third-generation cephalosporin was considered
adequate. Inadequate treatment was defined as treatment
without adequate coverage of Streptococcus pneumoniae,
Haemophilus influenzae and/or Gram-negative enteric
bacilli (penicillin G with and without aminoglycosides,
first-generation cephalosporins, macrolides and cotrimox-
azol). Since the regular coverage of ‘atypical’ bacterial
pathogens with a macrolide was optional in the ERS
guidelines, its absence was not considered inadequate.
In severe CAP, any monotherapy and any combination
treatment without coverage of ‘atypical’ bacterial patho-
gens (with macrolides or second generation quinolones) was
considered inadequate. In addition to ERS guidelines,
aminoglycosides as part of an appropriate combination
regimen were accepted.
In case of suspected aspiration, aminopenicillin +b-
lactamase-inhibitor and clindamycin but also imipenem or
metronidazole were considered adequate candidates for the
coverage of pathogens usually associated with aspiration.
Antimicrobial overtreatment was defined as an adequate
antimicrobial coverage which might have been equally
achieved by less potent and cheaper antimicrobial agents.
Particularly, since the frequency of b-lactamase-producing
strains of Haemophilus influenzae in Germany is low, the
regular use of an aminopenicillin plus b-lactamase inhibitor
was considered as over-treatment.
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defined as persistent fever 38?38C and/or persistent clinical
symptoms (malaise, cough, expectoration or dyspnoea) or
clinical deterioration (development of acute respiratory
failure requiring ventilatory support and/or or septic shock)
after 72 h of in-hospital antimicrobial treatment.
EVALUATION OF PATIENT MANAGEMENT
The evaluation of patient management included (i) the
determination of severity patterns in the general hospita-
lized population and in patients admitted to the ICU; (ii)
the assessment of diagnostic work-up according to severity
of pneumonia; (iii) the analysis of initial antimicrobial
treatment (response rate, frequency of inadequacy and
antimicrobial overtreatment). Potential consequences of
inadequate antimicrobial treatment were determined by its
influence on outcome measurements (non-response to
initial antimicrobial treatment, duration of hospitalization,
30 day in-hospital mortality).
STATISTICS
Results are expressed as mean + standard deviation (SD).
Continuous variables were compared by Student’s t-test,
and categorical variables were compared by w2 test or by
Fisher’s exact test where appropriate. Comparisons of
continuous variables of more than two groups were
performed by one way ANOVA with post-hoc Bonferroni
correction. The level of significance was set at 5%.
Results
PATIENTS DESCRIPTIVES
Overall, 232 patients with CAP (mean age 69+17, range
19–93 years, 114 male, 118 female) were included in the
study. Twenty-three patients (10%) were admitted from
nursing-homes. A total of 120 patients (52%) had been
admitted to the hospital at least once within the last 2 years
(not within the last month), and 52 patients (22%) had a
history of previous pneumonia within that period.
Eighty-six patients (37%) were current smokers (410
cigarettes day71), and twelve (5%) were alcoholics (esti-
mated intake of 480 g alcohol day71). At least oneTABLE 1. Microbiological investigations according to severity o
Risk class Blood cultures n (%) Bronchoscopy with
I 6 (33) 1 (6)
II 27 (69) 3 (8)
III 23 (47) 6 (12
IV 38 (41) 12 (13
V 19 (56) 1 (3)
Total 113 (49) 23 (10comorbid illness was present in 182 patients (88%),
including 54 (23%) with one, 86 (35%) with two, 34
(15%) with three, and 12 (5%) with four co-morbid
illnesses. These included cardiac illnesses (n=133), pul-
monary illnesses (n=66), arterial hypertension (n=51),
CNS disorders (n=47), diabetes mellitus (n=30), neoplas-
tic illnesses (n=23) renal illnesses (n=22), and hepatic
illnesses (n=4).
HOSPITAL AND ICU ADMISSION
Eighteen patients (8%) belonged to risk class 1, 39 (17%) to
risk classs II, 49 (21%) to risk class III, 92 (40%) to risk
class IV, and 34 (15%) to risk class V. According to the
given definitions, 55 hospitalized patients (24%) had mild
CAP (with a mortality risk of51%), 156 (67%) moderate,
and 21 patients (9%) severe CAP. No patient required ICU
admission after 5 days of hospital admission due to late
complications not related to initial severity.
Out of 21 patients admitted to the ICU, two were in risk
class II, one in risk class III, 10 in risk class IV, and eight in
risk class V. These numbers corresponded to 5%, 2%, 11%,
and 24% admissions to the ICU in each risk class,
respectively. Five additional patients had an indication
for ICU admission during hospital treatment but were not
admitted because of advanced age and debilitating illness:
these were in risk classes III (n=1), IV (n=1), and V (n=3).
Six of 21 patients (29%) with severe CAP required
mechanical ventilation.
MICROBIAL INVESTIGATION
Blood cultures were performed in 113 (49%) patients and
pleural fluid was obtained in five cases (2%): 101/180 (56%)
of patients with temperature 4388C at admission had a
blood culture, and 101/113 (89%) with blood culture had a
temperature 4388C. Bronchoscopy with bronchoalveolar
lavage (BAL) was performed in 23 (10%) patients, but only
in two occasions within 24 h after hospitalization. Four
bronchoscopies were performed in six mechanically venti-
lated patients. Sputum and serology were not done in any
case. Overall, 124 patients (54%) had at least one microbial
examination. There was no discernible association between
the frequency of microbial investigation and risk classes
(Table 1).f CAP
BAL n (%) Pleural Puncture n (%) Any n (%)
1 (6) 8 (44)
1 (3) 27 (69)
) 2 (4) 25 (51)
) 0 43 (47)
1 (3) 21 (62)
) 5 (2) 124 (54)
TABLE 2. Initial empiric antimicrobial treatment in 232 patients with community-acquired pneumonia
Antimicrobal treatment Mild n (%)
n=55
Moderate n (%)
n=21
Severe n (%)
n=21
Monotherapy 45 (82)* 121 (78)* 9 (43)
Penicillin G 3{ 1{ —
Aminopenicillin 7 30 5{
Aminopenicillin/b-lactamase inhibitor 18{ 51{ 3{
First-generation cephalosporin 1 2 —
Third-generation cephalosporin 2{ 6 1{
Macrolide 12 19{ —
Imipenem 1{ — —
Second generation quinolone 1{ 11{ —
Cotrimoxazole — 1{ —
Combination regimen (dual) 8 (15) 32 (21) 9 (43)*
Penicillin G+aminoglycoside — 1{ —
Aminopenicillin+aminoglycoside 2{ 1{ 2{
Aminopenicillin+clindamycin — 1{ —
Aminopenicillin/b-lactamse inhibitor
+first-generation cephalosporin
1{ — —
Aminopenicillin/b-lactamse inhibitor
+aminoglycoside
— 8{ 2{
Aminopenicillin/b-lactamse inhibitor
+second-generation quinolone
— 4{ —
Acylureidopenicillin+aminoglycoside — 1{ —
First-generation cephalosporin+
aminoglycoside
1{ 3{ 2{
Third-generation cephalosporin+
macrolide
— 3 —
Third-generation cephalosporin+
aminoglycoside
2{ 8{ 2{
Third-generation cephalosporin+
second-generation quinolone
1{ — —
Third-generation cephalosporin+
metronidazole
— 1 —
Second-generation quinolone+
aminoglycoside
1{ 1{ —
Second-generation quinolone+
clindamycin
— — 1{
Combination (triple) regimen 2 (4) 3 (2) 3 (14)*
Penicillin G+aminoglycoside+
macrolide
— 1{ —
Aminopenicillin+aminoglycoside+
metronidazole
— 1{ —
Aminopenicillin/b-lactamase inhibitor+
aminoglycoside+metronidazole
1{ — —
Third generation cephalosporin+
aminoglycoside+macrolide
— — 2
Third generation cephalosporin+
macrolide+metronidazole
— — 1
Third generation cephalosporin+
aminoglycoside+metronidazole
1{ 1{ —
*More frequently present at P50?05.
{Inadequate antimicrobial treatment.
{Over-treatment.
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A definite aetiology (blood culture, pleural eusion, and/or
BAL performed within 24 h after hospitalization) could be
determined in 11 patients. The following pathogens were
identified: Streptococcus pneumoniae (n=4), other Strepto-
cocci (n=1), Staphylococcus aureus (n=3), Enterobacter
spp (n=2), Proteus spp (n=1).
A further seven pathogens were determined by BAL
performed after 24 h (probably representing nosocomial
infections) in five patients: Haemophilus influenzae (n=1),
Escherichia coli (n=1), Klebsiella spp (n=2), Enterobacter
spp (n=2), Morganella spp (n=1).
Blood cultures were positive in 9/113 cases (8%), BAL
in 6/23 (26%) 1/2 (50%) of those performed within 24 h
after hospitalization, and pleural eusion cultures in 2/5
(40%).
AMBULATORY ANTIMICROBIAL
PRE-TREATMENT
Thirty-eight patients (16%) had received ambulatory
oral antimicrobial pre-treatment. This included aminope-
nicillin (n=5), cephalosporins (n=4), macolides (n=10),
cotrimoxazole (n=2), tetracyclin (n=10) and quinolones
(n=7).
INITIAL EMPIRIC ANTIMICROBIAL
TREATMENT
All patients received initial empiric antimicrobial treatment
shortly after admission. This included monotherapy in 175
patients (75%) and a combination regimen in 57 (25%).
The latter consisted of dual combination treatment in 49
(21%) and of triple combination treatment in eight (3%)
patients. The antimicrobial agents administered are sum-
marized in Table 2. Monotherapy was significantly more
frequent in mild and moderate CAP, and combination
therapy in severe CAP (P50?05). Accordingly, there was a
trend to administer a combination regimen in higher risk
classes [2/18 (11%) in risk class I, 10/39 (26%) in risk class
II, 9/49 (23%) in risk class III, 24/92 (26%) in risk class IV,
and 12/34 (35%) in risk class V].
Overall, 169/232 patients (73%) received an antimicro-
bial treatment considered as not optimal [62 (27%)
inadequate treatment, 107 (46%) over-treatment].
Inadequate initial empiric antimicrobial treatment as
defined above was present in 5/55 patients (9%) with mild,
39/156 patients (25%) with moderate, and 18/21 (86%)
with severe CAP. Antimicrobial treatment was significantly
more often inadequate in severe than in mild and moderate
CAP (P50?0001).
Conversely, overtreatment was present in 30/55 (55%)
patients with mild, 77/156 (49%) with moderate, and 0/21
(0%) with severe CAP. Overtreatment occurred signifi-
cantly more often in mild and moderate than in severe CAP
(P50?0001). Overtreatment in mild and moderate CAP
mainly included monotherapy with an aminopenicillin plus-lactam-inhibitor (n=69, 65%) and combination regimen
with aminoglycosides (n=27, 25%).
Overall, 49 patients (21%) did not respond to initial
empiric antimicrobial treatment. Non-responders were
similarly distributed over all risk classes [5/18 (27%) risk
class I, 7/39 (18%) risk class II, 13/49 (27%) risk class III,
16/92 (17%) risk class IV, 8/34 (24%) risk class V]. There
was a trend close to significance for inadequate initial
empiric antimicrobial treatment to be more frequent in
non-responders as compared to responders [18/62 (29%) vs.
31/170 (18%), RR 1?6 95% Cl 0?9–2?6, (P=0?07)]. This
trend was evident in all severity groups but most obvious in
the group with severe pneumonia [mild pneumonia 2/5
(40%) vs. 10/50 (20%); moderate pneumonia 9/39 (23%) vs.
21/117 (18%); severe pneumonia 7/18 (39% ) vs. 0/3 (0%)].
The duration of hospitalization was significantly longer in
patients with inadequate initial empiric antimicrobial
treatment (17+11 vs. 14+8 days, P=0?03). Again, the
corresponding dierence was consistently apparent in all
groups but most pronounced in the group with severe
pneumonia (mild pneumonia 13+11 vs. 11+8 days;
moderate pneumonia 16+8 vs. 15+8 days; severe pneu-
monia 21+15 vs. 13+4 days). However, there was no
significant dierence in survival in the presence
of inadequate initial empiric antimicrobial treatment [5/62
(8%) vs. 10/170 (6%), RR 1?4 95% Cl 0?5–3?9, P=0?55].
OUTCOME
The mean duration of hospitalization was 14?8+9?1 days.
Stratification of the duration of hospitalization according
to risk classes is given in Table 3. Patients with severe CAP
were hospitalized significantly longer than those with mild
and moderate CAP (mild CAP 11?4+8?7, moderate CAP
15?3+7?9 and severe CAP 19?6+13?9 days; P50?001).
Accordingly, the duration of hospitalization was signifi-
cantly longer in risk class IV as compared to risk class II
when all patients were taken into account, and in risk
classes IV and V when only survivors were included.
Fifteen patients (7%) died, including five patients treated
in the ICU (24%). No patient died in risk classes I and II,
one in risk class III (2%), five in risk class IV (5?5%), and
nine in risk class V (26?5%).
Discussion
In this study evaluating routine management of CAP in a
primary care hospital, two principal management policies
were obvious. These included (i) an individualized diag-
nostic and antimicrobial treatment approach and (ii) the
general limitation of diagnostic evaluation to blood cultures
and occasionally pleural fluid puncture and bronchoscopy
with bronchoalveolar lavage. The application of standar-
dized criteria in the evaluation of this practice resulted in
several important insights: (i) 1/4 (25%) of the hospitalized
patient population had a mortality risk 51% and, there-
fore, may have been treated preferably as outpatients; (ii)
diagnostic testing was not applied according to severity of
CAP; (iii) whereas in mild CAP inadequate antimicrobial
TABLE 3. Duration of hospitalization in patients with CAP according to risk class
Number of patients n (%) Duration of hospital stay (days)
Risk class All Only survivors
18 11?8+9?0 11?8+9?0
II 39 11?2+8?4 11?2+8?4
III 49 15?2+7?9 15?4+7?8
IV 92 16?2+7?9* 16?4+7?8*
V 34 15?9+12?7 18?7+12?7**
*P=0?025; **P=0?0028.
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the reverse was true for severe CAP; (iv) inadequate
antimicrobial treatment was present in 27% of patients,
and was associated with a higher primary treatment failure
and longer duration of hospitalization but not with
increased mortality.
The population studied was comparable to the two
largest corresponding unicentre series on CAP reported in
the literature in terms of age, sex, and comorbidity (10,11).
Also the overall response rate to initial antimicrobial
treatment (79%) was similar to other reports (12,13). The
definition of severe CAP may be subject to concern since
‘admission to the ICU’ does not represent an independent
criterion. However, no universally accepted definition of
severe CAP is available, and all series dealing with severe
CAP in the literature refer to patients admitted to the ICU.
In fact, the mortality of 7% in the general population and
24% in severe CAP was in the range of the expected (14–
17). Finally, mortality rates were very similar to those
found by Fine et al. for the MedisGroups and inpatients
Port validation cohorts (0, 0, 2?0, 5?5 and 26?6% for risk
classes I–V in our study as compared to 0, 0?6, 2?8, 8?2 and
29?2 and 0, 0?9, 1?2, 9?0 and 27?1%, respectively) (8).
One of the most striking findings in this evaluation of
management of patients with CAP was the high proportion
of hospitalized patients who may have been primarily
candidates for ambulatory treatment. Consistent with
another recent report (18), social reasons may have
impeded ambulatory treatment in some cases and, as a
matter of fact, two patients with risk class II required
admission to the ICU. Unfortunately, the study design did
not allow determination of the exact rate of extramedical
reasons for hospital admissions in our series. Nevertheless,
our data suggest that the implementation of the criteria for
the identification of patients at low risks as defined by Fine
et al. in general practice and primary hospitals bears a
considerable potential for cost saving.
The regular diagnostic approach of hospitalized patients
did not include sputum, serology and antigen-testing but
was confined to blood cultures and pleural fluid puncture
where appropriate. Therefore, the findings of this study are
applicable only to settings with similar diagnostic facilities.
The rationale of recommending blood cultures only inpatients with a temperature 4388C in the ERS guidelines
may be questioned. In any case, blood cultures were only
slightly more frequently obtained in patients with a
temperature 4388C, nevertheless, the diagnostic yield of
blood cultures was 8% and, thereby, in the expected range
(19,20). Bronchoscopy was applied individually, mainly in
patients with primary treatment failures or with suspected
obstructing bronchial tumours. Cultures of BALF were
qualitative only, however, the recommendation in the ERS
guidelines to use quantitative cultures at least in mechani-
cally ventilated patients is not supported by evidence from
prospective studies. In this series, the yield of qualitative
BALF cultures was considerably low (16%), confirming the
few data available in the literature (21,22). The diagnostic
evaluation was not extended in patients with higher risk
classes. Overall, the diagnostic policy used in this hospital
must be interpreted on the background of the absence of a
local microbiological laboratory and the prospect of having
to send any respiratory secretions by mail. Whether this
practice is cost-eective under the given circumstances
remains to be determined. Surprisingly, positive results of
blood cultures and bronchoscopy were not significantly
more likely in higher risk classes. Although it is not possible
to argue in favour of a risk-adapted diagnostic work-up in
light of the results of the present study, it seems reasonable
to assume that patients with severe CAP have the highest
benefit from diagnostic results (22).
Overtreatment was found to be frequent in mild and
moderate CAP. The majority of overtreatment was due to
monotherapy with aminopenicillins including b-lactamase
inhibitors and combination regimen including aminoglyco-
sides. This apparent trend for extended or double coverage
in patients with non-severe CAP, especially with aminogly-
cosides, clearly should be discouraged.
Adequacy of the initial empiric antimicrobial treatment
was classified according to ERS guidelines and modified
according to susceptibility patterns reported from dierent
German regions (9). Following these criteria, it was found
to be inadequate in a considerable amount of cases (27%).
The particularly high rate of inadequate antimicrobial
treatment in patients with severe CAP represents a serious
concern. However, in the absence of a defined microbial
pattern of the local setting, any classification of the initial
562 S. EWIG ET AL.empiric antimicrobial treatment may be hazardous. This is
especially true for the classification of quinolones and
macrolides. For example, despite the view that monother-
apy with second-generation quinolones such as ofloxacin
and ciprofloxacin is inadequate in CAP because of
relatively high MICs for Streptococcus pneumoniae, at least
one large study could demonstrate good treatment results
with ofloxacin in patients with CAP (23) and another with
ciprofloxacin in severe CAP (13). Moreover, monotherapy
with macrolides in hospitalized patients not admitted to the
ICU may be adequate in a population with a low incidence
of Haemophilus influenzae and GNEB, whereas the absence
of macrolides in severe CAP may equally represent an
adequate regimen in a population with a low incidence of
‘atypical’ pathogens, particularly of legionellosis. Never-
theless, having these limitations in mind, inadequate initial
antimicrobial treatment was associated with a higher
proportion of primary treatment failures and a longer
duration of hospitalization. These dierences were most
pronounced in the group with severe CAP. These findings
clearly indicate that inadequate antimicrobial treatment
does aect outcome measurements which bear important
economic implications. On the other hand, in contrast to
findings of others in patients with severe CAP (24,25), we
did not find a significant association of inadequate initial
antimicrobial treatment with mortality. However, in view
of the limited number of deaths in this series, this lacking
association should be interpreted with caution.
In conclusion, the main prospects for a future interven-
tional study are the consideration of ambulatory treatment
in low risk patients and the reduction of overtreatment in
hospitalized patients with non-severe CAP. The eect of
extended microbial investigation on the outcome of severe
CAP remains to be determined. Finally, current antimicro-
bial treatment guidelines may be useful in terms of
optimizing cost-eectiveness in the management of patients
with CAP.
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